Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence

Addiction

Volumn 107, Issue 2, 2012, Pages 361-369

  Ling, Walter ^a   Shoptaw, Steven ^a   Hillhouse, Maureen ^a   Bholat, Michelle A ^a   Charuvastra, Charles ^b   Heinzerling, Keith ^a   Chim, David ^a   Annon, Jeffrey ^a   Dowling, Patrick T ^a   Doraimani, Geetha ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mission Community Hospital   (United States)

Author keywords

Methamphetamine; Pharmacotherapy; PROMETA protocol; Substance abuse treatment

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; FLUMAZENIL; GABAPENTIN; HISTAMINE AGONIST; HYDROXYZINE; METHAMPHETAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG COMBINATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT;

ADULT; AMINES; AMPHETAMINE-RELATED DISORDERS; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FLUMAZENIL; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HISTAMINE AGONISTS; HUMANS; HYDROXYZINE; INFUSIONS, INTRAVENOUS; MALE; MEDICATION ADHERENCE; METHAMPHETAMINE; SELF REPORT;

EID: 84855931944     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03619.x     Document Type: Article

References (27)

1. United Nations Office on Drugs and Crime. World Drug Report, 2008. Vienna, Austria: United Nations; 2008.
2. Office of Applied Statistics, Substance Abuse and Mental Health Services Administration (SAMHSA). The NSDUH Report. Methamphetamine Use, Abuse, and Dependence: 2002, 2003, and 2004 2005. Available at: (accessed 20 September 2011; archived by Webcite at ).
3. Office of Applied Statistics, Abuse and Mental Health Services Administration (SAMHSA). National Survey on Drug Use and Health: National Findings 2007. Available at: (accessed 20 September 2011; archived by Webcite at ).
4. Lee N. K., Rawson R. A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008; 27: 309-17.
5. Marinelli-Casey P., Hillhouse M. P., Rawson R. 12-Step participation of methamphetamine-dependent adults previously participating in the Methamphetamine Treatment Project (MTP). Presented at the annual meeting of the College on Problems of Drug Dependence, June 2006, Scottsdale, AZ.
6. Goldstein R. Z., Volkow N. D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159: 1642-52.
7. Tiihonen J., Kuoppasalmi K., Fohr J., Tuomola P., Kuikanmaki O., Vorma H. etal. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007; 164: 160-2.
8. Vocci F. J., Elkashef A., Appel N. M. Pharmacological treatment of methamphetamine addiction. Roll J. M., Rawson R. A., Ling L., Shoptaw S., editors. Methamphetamine Addiction: From Basic Science to Treatment. New York: Guilford Press; 2009, p. 202-29.
9. Elkashef A. M., Rawson R. A., Anderson A. L., Li S. H., Holmes T., Smith E. V. etal. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008; 33: 1162-70.
10. Shoptaw S., Heinzerling K. G., Rotheram-Fuller E., Steward T., Wang J., Swanson A. N. etal. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008; 1: 222-32.
11. Brodie J. D., Figueroa E., Laska E. M., Dewey S. L. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 55: 122-5.
12. Roberge R. J., Lin E., Krenzelok E. P. Flumazenil reversal of carisoprodol (Soma) intoxication. J Emerg Med 2000; 18: 61-4.
13. Rubio F., Quintero S., Hernandez A., Fernandez S., Cozar L., Lobato I. M. etal. Flumazenil for coma reversal in children after cannabis. Lancet 1993; 341: 1028-9.
14. Ito K., Ohmori T., Abekawa T., Koyama T. The role of benzodiazepine receptors in the acquisition and behavioral expression of sensitization to methamphetamine. Pharmacol Biochem Behav 2000; 65: 705-10.
15. Dougherty J. A., Rhoney D. H. Gabapenta unique anti-epileptic agent. Neurol Res 2001; 23: 821-9.
16. Maneuf Y. P., Gonzalez M. I., Sutton K. S., Chung F. Z., Pinnock R. D., Lee K. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 2003; 20: 742-50.
17. Myrick H., Henderson S., Brady K. T., Malcolm R., Measom M. Divalproex loading in the treatment of cocaine dependence. J Psychoact Drugs 2001; 33: 283-7.
18. Raby W. N. Gabapentin therapy for cocaine cravings. Am J Psychiatry 2000; 157: 2058-9.
19. Hart C. L., Ward A. S., Collins E. D., Haney M., Foltin R. W. Gabapentin maintenance decreases smoked cocaine related subjective effects, but not self-administration by human. Drug Alcohol Depend 2004; 73: 279-87.
20. Brower K. J. Insomnia, alcoholism and relapse. Sleep Med Rev 2003; 7: 523-39.
21. Spitzer R. L., Williams J. B., Gibbon M., First M. B. The Structured Clinical Interview for the DSM-IV (SCID). Washington, DC: American Psychiatric Press; 1995.
22. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: Author; 1994.
23. Stout R. L., Wirtz P. W., Carbonari J. P., Del Boca F. K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol 1994; 12: 70-5.
24. Carroll K. M. A Cognitive-Behavioral Approach: Treating Cocaine Addiction. NIDA Therapy Manuals for Drug Addiction. Bethesda, MD: Department of Health and Human Services; 1998.
25. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. etal. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
26. Mezinskis J., Dryenforth S., Goldsmith R., Cohen R., Somoza E. Craving and withdrawal symptoms for various drugs of abuse. Psychiatr Ann 1998; 28: 577-83.
27. Urschel H. C. III, Hanselka L. L., Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence. J Psychopharmacol 2011; 25: 254-62.